CADIS HealthTech, Inc. – Trademark Portfolio

Entity Type: 03

CADIS HealthTech, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 4 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 1 trademark is registered and 4 are pending. Notable registered marks include EZIEXPERT. The owner is based in Albuquerque, NM.

8808 Scarlet Knight NE

Albuquerque, NM 87122

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CADIS HealthTech, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (4 filings)

Scientific and technological services; industrial analysis and research services

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does CADIS HealthTech, Inc. have?

CADIS HealthTech, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 4 pending.

What trademark classes does CADIS HealthTech, Inc. file in?

CADIS HealthTech, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 10 (Medical Apparatus). Class 42 covers scientific and technological services; industrial analysis and research services.

What are CADIS HealthTech, Inc.'s most well-known trademarks?

CADIS HealthTech, Inc.'s registered trademark portfolio includes well-known marks such as EZIEXPERT. These are among 1 currently registered trademark in the portfolio.

What is CADIS HealthTech, Inc.'s trademark registration success rate?

CADIS HealthTech, Inc. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 4 applications are pending review.